These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32940328)

  • 21. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroprevalence of SARS-CoV-2 in Pakistan: an update on epidemiological trends.
    Waqar M; Wahid B; Idrees M; Ali M; Rehman Z
    Z Naturforsch C J Biosci; 2021 Sep; 76(9-10):425-429. PubMed ID: 34161693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
    van Dam P; Huizing M; Roelant E; Hotterbeekx A; De Winter FHR; Kumar-Singh S; Moons P; Amajoud Z; Vulsteke C; Croes L; Janssens A; Berneman Z; Prenen H; Meuris L; Vanden Berghe W; Smits E; Peeters M
    Eur J Cancer; 2021 May; 148():328-339. PubMed ID: 33773276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland.
    Kasztelewicz B; Janiszewska K; Burzyńska J; Szydłowska E; Migdał M; Dzierżanowska-Fangrat K
    PLoS One; 2021; 16(4):e0249550. PubMed ID: 33793673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
    Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
    BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals.
    Alserehi HA; Alqunaibet AM; Al-Tawfiq JA; Alharbi NK; Alshukairi AN; Alanazi KH; Bin Saleh GM; Alshehri AM; Almasoud A; Hashem AM; Alruwaily AR; Alaswad RH; Al-Mutlaq HM; Almudaiheem AA; Othman FM; Aldakeel SA; Abu Ghararah MR; Jokhdar HA; Algwizani AR; Almudarra SS; Albarrag AM
    Diagn Microbiol Infect Dis; 2021 Mar; 99(3):115273. PubMed ID: 33296851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers & implications of infection control practice in India.
    Gupta R; Dwivedi T; Gajendra S; Sahoo B; Gupta SK; Vikas H; Singh AR; Mohan A; Bhatnagar S; Singh S; Wundavalli L; Guleria R
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):207-213. PubMed ID: 33642348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut.
    Papasavas P; Olugbile S; Wu U; Robinson K; Roberts AL; O'Sullivan DM; McLaughlin T; Mather JF; Steinberg AC; Orlando R; Kumar A
    J Hosp Infect; 2021 Aug; 114():117-125. PubMed ID: 33930487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disparities in Seroprevalence of SARS-CoV-2 Immunoglobulin Antibodies in a Large Midwestern Health Care System.
    Fitzpatrick V; Rivelli A; Blair C; Copeland K; Richards J
    Public Health Rep; 2021 May; 136(3):361-367. PubMed ID: 33673779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan: A cross-sectional study.
    Nishida T; Iwahashi H; Yamauchi K; Kinoshita N; Okauchi Y; Suzuki N; Inada M; Abe K
    Medicine (Baltimore); 2021 Jun; 100(25):e26433. PubMed ID: 34160433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study.
    Hildebrandt A; Hökelekli O; Uflacker L; Rudolf H; Gatermann SG
    Int J Hyg Environ Health; 2021 Jun; 235():113771. PubMed ID: 34049092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.
    Kim YK; Minn D; Song DY; Lee CH; Ryoo NH; Jeon CH; Song KE; Suh JS; Chang SH
    J Korean Med Sci; 2021 Nov; 36(43):e294. PubMed ID: 34751011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.
    Ladoire S; Rederstorff E; Goussot V; Parnalland S; Briot N; Ballot E; Truntzer C; Ayati S; Bengrine-Lefevre L; Bremaud N; Coudert B; Desmoulins I; Favier L; Fraisse C; Fumet JD; Hennequin A; Hervieu A; Ilie S; Kaderbhai C; Lagrange A; Martin N; Mazilu I; Mayeur D; Palmier R; Simonet-Lamm AL; Vincent J; Zanetta S; Arnould L; Coutant C; Bertaut A; Ghiringhelli F
    Eur J Cancer; 2022 Apr; 165():13-24. PubMed ID: 35189537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review.
    Byambasuren O; Dobler CC; Bell K; Rojas DP; Clark J; McLaws ML; Glasziou P
    PLoS One; 2021; 16(4):e0248946. PubMed ID: 33798211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Seroprevalence of SARS-CoV-2 (COVID-19)-Specific Antibodies among Healthcare Workers: A Cross-Sectional Study in Guilan, Iran.
    Balou HA; Yaghubi Kalurazi T; Joukar F; Hassanipour S; Shenagari M; Khoshsorour M; Mansour-Ghanaei F
    J Environ Public Health; 2021; 2021():9081491. PubMed ID: 34691195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia.
    Alhazmi A; Alamer E; Abdelwahab S; Khamjan N; Hamami A; Haddad M; Darraj M; Hashem AM; Algaissi A
    Int J Environ Res Public Health; 2021 Nov; 18(23):. PubMed ID: 34886175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.
    Iruretagoyena M; Vial MR; Spencer-Sandino M; Gaete P; Peters A; Delgado I; Perez I; Calderon C; Porte L; Legarraga P; Anderson A; Aguilera X; Vial P; Weitzel T; Munita JM
    BMC Infect Dis; 2021 May; 21(1):478. PubMed ID: 34039287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
    Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
    JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.